Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: FIrst-Time Three-Year Results of the TRUCKEE Study

Document Type

Conference Proceeding

Publication Date

6-2025

Publication Title

Investigative Ophthalmology and Visual Science

Abstract

Purpose : Faricimab was FDA-approved for neovascular age-related macular degeneration (nAMD) in Jan 2022. This multi-center, retrospective study evaluates the safety and efficacy of faricimab in real-world patients diagnosed with nAMD.

Methods : This study investigates both treatment-naïve patients and patients switched to faricimab from other anti-VEGF agents. Data collected included demographics, treatment history, best-corrected visual acuity (BCVA), central subfield thickness (CST), and presence of subretinal or intraretinal fluid (SRF or IRF). Snellen visual acuity was converted to Early Treatment Diabetic Retinopathy Study (ETDRS) scoring. Improvements in visual acuity and CST are evaluated as averages. Improvements in retinal fluid are evaluated as a proportion. Observed and calculated data is reported. Safety is summarized.

Results : A total of 3607 eyes across 2877 patients were recorded. The average age was 80.31 years, 49.1% were female and 40.9% had switched from aflibercept. All eyes switched from any anti-VEGF post three injections of faricimab (n=1746) had a BCVA increase of 0.48 letters (p=0.4107), a CST decrease of 28.53um (p< 0.0001), and SRF/IRF resolution rates of 22.5% and 28.5%. Eyes switched from aflibercept post three injections of faricimab (n=1007) had a BCVA increase of 0.74 letters (p=0.1193), a CST decrease of 25.00um (p< 0.0001), and SRF/IRF resolution rates 23.2% and 29.6%. All eyes switched from any anti-VEGF post nine injections of faricimab (n=376) had a BCVA increase of 0.53 letters (p=0.9292), a CST decrease of 35.06um (p< 0.00001), and SRF/IRF resolution rates of 26.0% and 45.8%. Eyes switched from aflibercept post nine injections of faricimab (n=232) had a BCVA decrease of 0.41 letters (p=0.0926), a CST decrease of 35.14um (p=0.0001), and SRF/IRF resolution rates 25.5% and 43.2%. Intraocular inflammation was noted at a rate of 0.11% per injection.

Conclusions : Faricimab has demonstrated efficacy via anatomic and visual parameters, in previously treated patients, a demographic not studied in the trials leading to FDA-approval. Safety is comparable to current agents. Future results will continue to investigate the long-term safety, efficacy and durability of faricimab in real-world patients with nAMD. First-time three-year data will be presented at ARVO 2025.

Volume

66

Issue

8

First Page

717

Comments

Association for Research in Vision and Ophthalmology ARVO Annual Meeting, May 4-8, 2025, Salt Lake City, UT

Last Page

717

Link to Full Text

Share

COinS